PATENT CLAIM ANALYSIS

Application Number: 15874430
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "006900"]

Abstract:
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

Claim (Index 9):
The method of  claim 1  wherein the key elements of metabolic disorders are selected from the group consisting of of impaired fasting glucose, impaired glucose tolerance, increased waist circumference, increased visceral fat content, increased fasting plasma glucose, increased fasting plasma triglycerides, increased fasting plasma free fatty acids, decreased fasting plasma high density lipoprotein level, increased systolic or diastolic blood pressure, increased plasma postprandial triglyceride or free fatty acid levels, increased cellular oxidative stress or plasma indicators thereof, increased circulating hypercoagulative state, arteriosclerosis, coronary artery disease, peripheral vascular disease, congestive heart failure, hepatic steatosis, renal disease including renal insufficiency, and cerebrovascular disease

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.23529
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15165485', '14506353', '13375810', '12154907', '14048880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.79176533231629
- 35 USC 102 Novelty (BERT): 0.6474376426966383
- Combined Prediction Score: 0.7773325633543249
- Mean Citation Score: 473.91606
- Max Citation Score: 599.9459
- Similarity Product: 592.4571324727774

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test